Half-year report · Q2
9989.TEDINET S100URME
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥395.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥751.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥371.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥21.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥20.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥20.8bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥41.7bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.0bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥20.5bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20.6bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥14.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥420.0bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥420.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥369.9bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥159.2bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥167.1bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥260.8bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥253.1bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥244.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥63.4bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥69.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥63.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥69.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥76.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥80.9bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥41.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥23.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥18.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥74.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥21.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥7.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥22.5bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥122.02 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥249.07 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.2 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 62.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.1% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥28.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥28.5bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥168.4bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥168.4bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6m |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥8.6bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥255.6bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥227.2bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥28.5bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥424.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥395.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥28.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥21.2bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥26.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥26.1bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥155.0bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥155.0bn |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5m |
| jpcrp040300-q2r_E03226-000Discount Storereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥7.5bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥242.8bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥216.7bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥26.1bn |
| jpcrp040300-q2r_E03226-000Drug Storereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥397.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥371.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥26.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥20.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 506
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |